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Background: Acute myeloid leukemia (AML) is a life-threatening malignancy with limited 
treatment options in chemotherapy-refractory patients. A first-in-human dose study was designed 
to investigate a safe and biologically effective dose range for LY2457546, a novel multikinase 
inhibitor, in patients with relapsed AML.
Methods: In this nonrandomized, open-label, dose escalation Phase I study, LY2457546 was 
administered orally once a day. Safety, pharmacokinetics, changes in phosphorylation of target 
kinases in AML blasts, and risk of drug–drug interactions (DDI) were assessed.
Results: Five patients were treated at the starting and predicted minimal biologically 
effective dose of 50 mg/day. The most commonly observed adverse events were febrile   
neutropenia, epistaxis, petechiae, and headache. The majority of adverse events (81%) were 
Grade 1 or 2. One patient had generalized muscle weakness (Grade 3), which was deemed to be 
a dose-limiting toxicity. Notably, the pharmacokinetic profile of LY2457546 showed virtually 
no elimination of LY2457546 within 24 hours, and thus prevented further dose escalation. No 
significant DDI were observed. Ex vivo flow cytometry studies showed downregulation of the 
phosphoproteins, pcKIT, pFLT3, and pS6, in AML blasts after LY2457546 administration. 
No medically relevant responses were observed in the five treated patients.
Conclusion: No biologically effective dose could be established for LY2457546 in 
  chemotherapy-resistant AML patients. Lack of drug clearance prevented safe dose escalation, 
and the study was terminated early. Future efforts should be made to develop derivatives with 
a more favorable pharmacokinetic profile.
Keywords: multikinase inhibitor, pharmacokinetics, safety, acute myeloid leukemia, 
pharmacodynamics
Introduction
Acute myeloid leukemia (AML) is a heterogeneous disorder of hemopoietic stem cells.1 
Despite improved treatment of AML in recent years, the outcome remains dismal, with 
only approximately 30% of patients showing long-term survival.2   Factors determining 
survival include age, cytogenetic aberrations, number of previous antileukemia treatments, 
and molecular defects in leukemic cells.1–3 In patients with a normal karyotype, mutations 
in certain oncogenic kinases, such as FLT3 or KIT,4 determine the prognosis in AML.3,5–15 
Blast cell proliferation and dissemination may be triggered by additional factors, including 
expression of certain homing receptors and the bone marrow microenvironment.16–23
A number of pharmacologic approaches have been   proposed to counteract leu-
kemic cell growth in AML. A straightforward approach is to develop multikinase Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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inhibitors acting on one or more critical signaling pathways 
associated with leukemic cell growth, proliferation, and/or 
differentiation.24 In fact, various multikinase inhibitors can 
simultaneously inhibit multiple signaling pathways involved 
in AML cell growth and survival.25–34
LY2457546 is a novel multikinase inhibitor with 
properties similar to LY2401402, which was previously 
shown to have an antileukemic effect in MV4-11 cells 
containing an FLT3-ITD mutation.35,36 LY2457546 has 
a spectrum of kinase inhibition that is distinct from that 
of other multikinase inhibitors, including sunitinib. For 
example, LY2457546 inhibits several of the ephrins and 
Tie-237 (Table 1). Based on this information, a pharma-
cokinetic/pharmacodynamic model was developed using 
in vitro and in vivo animal data to   estimate the biologi-
cally effective dose range for LY2457546 in humans,38 
and to identify a safe starting dose for a first-in-human   
dose-escalation study in patients with AML. Using this pre-
dictive model, the primary objective of this study was to con-
firm the safety and the biologically effective dose range of 
LY2457546 in patients with AML. As secondary objectives, 
we evaluated the pharmacokinetic profile of LY2457546 and 
changes in pharmacodynamic markers (such as changes in 
phosphoprotein expression in circulating AML blasts) after 
Table 1 In vitro Inhibition Profile of LY21457546 
Human Kinases LY2457546 Sunitinib Sorafenib
Biochemical Inhibition Profile IC50 (μM)
FLT4  0.00156 0.00566 0.0261
RET  0.00419 0.0485 0.0033
FLT3 0.0051 0.00659 0.105
EPHA5  0.0107 8.05 0.531
EPHB1  0.0214 1.15 0.474
PDGF-Rb  0.0257 0.0352 0.312
KDR  0.028 0.0611 0.013
VEGF-R1  0.0306 0.269 0.241
EPHA8  0.0335 20 0.214
VEGF-R3  0.0341 0.0323 0.0925
EPHA2  0.0374 9.38 0.276
EPHB4  0.0398 1.59 0.727
EPHB2  0.0457 3.13 0.854
cKIT  0.0738 0.0756 0.966
EPHA3  0.0998 10.5 1.42
EPHA4  0.157 11.7 3.26
EPHA7  0.221 5.38 0.709
RAF  0.264 20 0.0195
EPHA1  0.616 7.08 nD
p70S6K
(percent inhibition at 
20 μM)
75.9 92.3 75.6
Cell-Based Target Inhibition Assays IC50 (mM)
Cell line Activator Phospho end  
point
LY2457546 Sunitinib Sorafenib
hUVeC VegF pERKT202Y204  0.00205 0.0287 nD
MV4-11 constitutively active pSTAT5Y694 0.00039 0.00426 nD
hUVeC VegF pERKpT202Y204  
(with BSA)
0.0414 0.0552 0.038
A2780 PDgF pAKTS473 0.0588 0.0169 1.33
ChO - 
Clone113
stable over-expression  
of Tie2
pTIE2pY99 0.166 >10 0.327
heK293-
Clone 25
stable over-expression  
of ephB4 
pEphB4Y590/Y596  0.0091 3.013 0.337
Cell-Based Antiproliferation Assay IC50 (μM)
LY2457546 Sunitinib Sorafenib
MV4-11 constitutively active (FLT3 iTD Mutation D835) 0.000339 0.0196 0.0117
Notes: aPercent inhibition at 20 μM; bstable overexpression of pTie2.
Abbreviations: hUVeC, human umbilical endothelial vascular cells; nD, not determined; BsA, bovine serum albumin.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
159
Dose study of multikinase inhibitor LY2457546
LY2457546 administration. Moreover, the potential risk of 
drug–drug interactions by combining LY2457546 with drugs 
known to be metabolized by cytochrome P450 (CYP) 3A4, 
CYPP2D6, and CYP2C9 were assessed.
Materials and methods
study design
This first-in-human monotherapy safety study was 
divided into three parts to evaluate a possible drug–drug 
interaction risk of LY2457546, and to confirm the 
predicted   pharmacokinetic/pharmacodynamic rela-
tionship of LY2457546 in humans (Figure 1). The 
first part (visit 0) consisted of a single-dose, 48-hour 
pharmacokinetic profile evaluation of LY2457546 (from day 
day -2 to day 1) and a baseline assessment of a drug–drug 
interaction cocktail. The second part (visit 1) was a mul-
tidose assessment for four weeks (for two weeks after an 
amendment) of daily oral administration of LY2457546. 
During visit 1, a 12-hour pharmacokinetic profile of 
LY2457546 was obtained. The third part (visit 2) evalu-
ated the 48-hour pharmacokinetic profile of LY2457546 in 
the presence of the drug–drug interaction cocktail after 
LY2457546 was stopped. Treatment was resumed as daily 
dosing for the remainder of the study, provided the patient 
showed clinical benefit.
The study was approved by the ethics committee of the 
Medical University of Vienna and the Austrian Federal Min-
istry of Health according to the International Conference on 
Harmonization guidelines, the Declaration of Helsinki on 
clinical trials involving human subjects, the recommendation 
for conducting clinical first-in-human dose studies by the 
  Committee For Medicinal Products For Human Use (www.emea.
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Figure 1 Design of the first-in-human dose study with LY2457546. To evaluate the safety, pharmacokinetics, DDI risk, and pharmacodynamic effects of single-dose (visit 
0) and multiple-dose (visit 1, visit 3n) administration of LY2457546, patients first underwent a bone marrow aspirate, which was repeated after multiple-dosing for four 
weeks (two weeks after amendment, visit 2). During visit 1, patients’ peripheral blast cell counts and changes in phosphoprotein expression were assessed daily and weekly, 
respectively. The DDi cocktail was administered prior to taking a single dose (approximately seven days prior to the single dose of LY2457546) and again after two or four 
weeks (after amendment) of multiple doses of LY2457546 (visit 2). The pharmacokinetic profile of LY2457546 was evaluated in the absence of the DDI cocktail as a single 
dose (48-hour profile) and again after one week of multiple dosing (12-hour profile).
Abbreviations: DDi, drug–drug interaction; AML, acute myeloid leukemia; LY, LY2457546.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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europa.eu/pdfs/human/swp/2836707enfin.pdf from August 
20, 2007, and the Austrian Medicinal Products Act (AMG).
enrolment criteria
The inclusion criteria were: age at least 18 years; diag-
nosis of relapsed or refractory AML; ineligibility for 
bone marrow transplantation or induction/consolidation 
chemotherapy;39 $10% of blasts in peripheral blood at 
baseline; willingness to undergo two bone marrow aspirates 
during visits 0 and 2 to evaluate changes in phosphopro-
tein expression in AML blasts; recovery from the acute 
toxic effects of previous treatment; performance status 
0 to 2 on the Eastern Cooperative Oncology Group scale;     
discontinuation of all previous therapies for cancer for at 
least 14 days (hydroxyurea used to control the peripheral 
blast cell count was permitted until 72 hours before study 
drug administration at visit 1); bilirubin #2 × below the 
upper limit of normal, alanine aminotransferase and aspar-
tate aminotransferase #5 × upper limit of normal; serum 
  creatinine #1.5 × upper limit of normal; no known active 
renal disease; activated prothrombin time and prothrombin 
time at or below upper limit of normal. Male and female 
patients agreed to use a reliable method of birth control 
during dosing and for six months following the last dose 
of study drug. Females of childbearing potential had to 
have had a negative serum pregnancy test at least seven 
days prior to the first dose of study drug. Monthly preg-
nancy tests were conducted in accordance with Article 30 
of the AMG. Finally, patients had to be compliant with 
all protocol-defined procedures and be able to swallow   
capsules.
Patients were excluded if they had acute promyelocytic 
leukemia as defined by World Health Organization criteria,39 
chronic myeloid leukemia in blast crisis, leukemic involve-
ment of the central nervous system (eg, signs, symptoms or 
a history of leukemic meningitis, must have had a negative 
lumbar puncture within two weeks of study enrolment), 
serious concomitant disorders (eg, active bacterial, fungal, 
or viral infection), active second primary malignancy that 
could affect study conduct or interpretation of study results, 
serious pre-existing medical conditions (eg, persistent history 
of occlusive coronary artery disease, uncontrolled hyperten-
sion with systolic 140 mmHg and diastolic 90 mmHg, 
risk of bleeding due to active gastrointestinal bleeding or 
anticoagulant therapy, except for low-dose therapy to main-
tain patency of central venous access devices), major surgery 
within four weeks of study enrolment, positive test results 
for human immunodeficiency virus antibodies, hepatitis B 
surface antigen, or hepatitis C antibodies, and women who 
were pregnant or lactating.
Drug formulation and schedule  
of administration
LY2457546 was taken as a once-daily oral capsule in the 
morning before breakfast. All patients had been fasting for 
approximately eight hours prior to the LY2457546 dose 
and for two hours prior to dosing of the drug cocktail. After 
oral administration, patients were asked to wait for at least 
60 minutes prior to having breakfast. For at least two weeks 
prior to the start of the study and until the final pharma-
cokinetic sample was collected, patients were requested to 
abstain from beverages containing grapefruit or pomelo 
fruit, and food containing broccoli, cabbage, cauliflower, 
turnips, collard, mustard, or charbroiled meats. If a patient 
continued taking dietary supplements, such as vitamins or 
St John’s wort, these were recorded as comedication and 
considered in the interpretation of the pharmacokinetic   
data.
Drug–drug interaction cocktail
The drug–drug interaction cocktail consisted of midazolam 
0.2 mg, dextromethorphan 30 mg, and tolbutamide 500 mg 
as specific probes to assess the CYP3A4, CYP2D6, and 
CYP2C9 metabolic pathways, respectively.40–43
Treatment assessment
Investigators assessed baseline “toxicity” according to 
institutional and previously published guidelines,44 which 
included establishing baseline neutropenia and other bone 
marrow deficiencies as a result of AML. Assessment of 
dose-limiting toxicity was graded following the National 
Cancer Institute’s Common Terminology Criteria for 
Adverse Events (CTCAE) version 3.0. The following adverse 
events were deemed to be dose-limiting toxicities if they 
were likely to be drug-related: $Grade 3 nonhematologi-
cal toxicity (except for nausea/vomiting without maximal 
symptomatic/  prophylactic treatment), CTCAE Grade 3 
or 4 febrile neutropenia, CTCAE Grade 3 infection with 
Grade 3 or 4 neutropenia, untreated diarrhea Grade $3, 
CTCAE Grade 4 neutropenia or thrombocytopenia until 
four weeks after the end of the treatment course, unless the 
respective Grade 4 cytopenia was   pre-existing. In patients 
who required platelet substitution to maintain a CTCAE 
Grade ,4 before treatment, a CTCAE Grade 4 thrombo-
cytopenia after   treatment did not constitute a dose-limiting   
toxicity.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Due to the cardiac toxicities observed with other mul-
tikinase inhibitors, the risks of developing Grade 3/4 QTc 
prolongation or increased blood pressure were evaluated. 
For QTc prolongation, the following dose-limiting toxicity 
definitions were used: any CTCAE Grade 4 QTc prolongation 
or three of six patients with CTCAE Grade 3 and a defini-
tive association between QTc prolongation and LY2457546 
exposure. Provided that other factors known to prolong 
QTc intervals had been minimized or excluded, assessment 
of QTc prolongation was based on Fridericia’s corrected 
QTc evaluation (QTcF) at the end of each cohort. In the 
event that CTCAE Grade 3 QTc prolongation was observed 
(defined as an interval 500 msec or an increase of QTc 
of 60 msec from baseline with no medically significant 
symptoms), a confirmatory 12-lead electrocardiogram was 
required before LY2457546 doses were omitted until the 
QTc interval returned to ,500 msec or below the 60 msec 
upper   boundary. In the event that CTCAE Grade 4 QTc pro-
longation was observed (defined as an interval 500 msec 
or an increase of QTc of 60 msec from baseline with life-
threatening signs or symptoms), patients would be considered 
for withdrawal from the study on the basis of dose-limiting   
toxicity.
Dose escalation
Dose escalation was planned up to the maximum toler-
ated dose. The decision to dose-escalate to the next cohort 
and dose level was planned on the basis of safety and avail-
able pharmacokinetic and pharmacodynamic data from the 
previous dose cohort. This decision was planned to occur 
in agreement with the investigators and sponsor. Written 
notification of this decision was to be sent to the site and 
appropriate institutional ethics committee. No intrapatient 
dose escalation beyond the original assigned cohort was 
permitted.
At the end of the first cohort, the pharmacokinetic pro-
files for the LY2457546 and drug cocktail were reviewed to 
confirm the predicted exposures for the following doses. The 
starting dose was 50 mg/day, and the maximum planned dose 
was 500 mg/day. The first cohort included three patients. For 
all subsequent doses where a pharmacological effect was 
expected, the cohort size was increased to six patients. All 
patients in a given cohort had to complete the first multidose 
cycle prior to enrolling patients at the next dose level. If two 
or more of six patients experienced a dose-limiting toxicity 
at any dose level, the maximum tolerated dose was exceeded 
and dose escalation ceased. For QTc prolongation, Grade 3 
QTc prolongation was required in three of six pts to declare 
a dose-limiting toxicity, while all Grade 4 QTc prolongations 
were declared as dose-limiting toxicity.
Pharmacokinetic assessment
Pharmacokinetic parameters were analyzed using standard, 
noncompartmental methods of analysis (WinNonlin Enter-
prise, version 5.2). It was planned to calculate the following: 
time to maximum concentration (Tmax), maximum plasma 
concentration (Cmax), area under the plasma concentration 
versus time curve (AUC), and oral clearance following 
LY2457546 administration.
Pharmacodynamic assessment
Based on the predictive pharmacokinetic/pharmacodynamic 
model, the biologically effective dose range was anticipated 
to be between 100 mg and 400 mg. The recommended bio-
logically effective dose should provide a minimum of 50% 
median inhibition of one or all phosphoproteins for 24 hours 
(the minimum requirement to declare a biologically effective 
dose would be based on pFLT3 inhibition), should provide 
durable AML blast reduction compared with baseline in at 
least half of the patients (for at least one month), and be lower 
than the maximum tolerated dose.
Flow cytometry
As previously described, blood samples were collected 
to evaluate phosphoprotein levels using flow cytometry.45 
In order to ensure appropriate assessment of changes in 
phosphoprotein expression, samples had to be shipped 
within 48 hours to a central laboratory (Esoterix, Mechelen, 
  Belgium) after blood or bone marrow aspirates were obtained. 
Upon arrival, cells were prepared for cytometric assessment, 
gated based on side versus forward scatter, and subsequently 
for CD45, CD34 (CD45-PerCP and CD34-PE, Becton 
Dickinson, San Jose, CA) and CD11b (CD11b-Pacific Blue, 
Beckman Coulter, Miami, FL, Esoterix custom conjugate) 
expression. This gating approach allowed the separation of 
four distinct subgroups, ie, CD34+CD11b-, CD34+CD11b+, 
CD34-CD11b-, and CD34-CD11b+. For each of these sub-
groups, the following phosphoproteins were determined 
with their respective isotype control (all antibodies were 
obtained from Cell Signaling Technology [CST], Danvers, 
MA): phospho-FLT3/CD135 (Y591-Alexa Fluor 647, 
CST,   Esoterix custom conjugate); phospho-c-KIT/CD117 
(Y719, No ST#3391L, CST); phospho-p44/42 extracellular 
  signaling-regulated kinase 1/2 (pERK1/2, T202/Y204, Alexa 
Fluor 647, No 4375, CST); phospho-AKT (S473-Alexa 
Fluor 647, No 4075, CST); phospho-phospho-tyrosine-Y100 Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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(pY100) (Alexa Fluor 488, No 9415, CST); phospho-S6 
ribosomal protein (pS6) (S235/236-Alexa Fluor 647, CST, 
Esoterix custom conjugate). Phospho-STAT5 was determined 
along with isotype control using anti-  phospho-STAT5 (Y694, 
No 612599, Becton Dickinson). The isotype controls used 
for the phosphoproteins were matched with the primary 
antibodies at the identical concentrations used in the assay. 
The phospho c-KIT (pcKIT) was developed using a goat-
antirabbit Alexa Fluor 647 (both used at 1 μg per staining 
reaction). In all cases, the staining reactions were carried out 
in 50 μL total volumes in phosphate-buffered saline with 
3.4% bovine serum albumin.
Flow cytometry was performed on a 3-laser Becton 
Dickinson FACS-Canto-II cytometer with custom filter sets 
designed to optimize the collection of Alexa 647 and Alexa 
700 signals, in lieu of tandem dyes. The instrument was set up 
using QC3 beads (Bangs Laboratories, Fishers, IN), Sphero-
tech 1 peak Rainbow Mid-Range beads (Spherotech, Lake 
Forest, IL), and CaliBrite APC beads (Beckton Dickinson) 
for the daily monitoring of instrument performance within 
an accepted “window of analysis”. Full spectrum fluorescent 
calibration particles (Spherotech) were also run with each 
assay to determine the molecules of equivalent fluorescence 
of the phosphoproteins. Each sample was analyzed using a 
direct data exchange link between WinList 6.0 (Verity Soft-
ware House, Topsham, MA) and Microsoft Excel (Microsoft, 
Redmond, WA). All data gating, displaying, and processing 
were conducted in WinList.
Antileukemia response assessment
Based on the recent World Health Organization criteria,46 
responses were determined by assessing bone marrow 
  aspirates. In this study, we also considered a pharmacody-
namic response if a sustained reduction in peripheral blast 
cell counts was observed (longer than four weeks).
Results
Five patients (A–E) were enrolled from February to August 
2009 and received 50 mg LY2457546 once daily. Except for 
one patient, all had an original diagnosis of primary AML. 
The median age of the patients was 68 years, with only one 
patient younger than 60 years (Table 2). The majority had 
been diagnosed with leukemia for at least 18 months. All 
patients had undergone at least a full regimen of induction 
  chemotherapy. Prior to entering the trial, all patients had 
received hydroxyurea to control blast cell counts. Two patients 
had medically treated hypertension at study entry, which did 
not deteriorate as a result of LY2457546 administration.
During visit 1, the first three patients were discontin-
ued from treatment on days 17, 20, and 30. The first two 
patients were discontinued due to disease progression. The 
third patient (C) showed Grade 3 muscle weakness on day 
10 which was considered to be drug-related and deemed 
a dose-limiting toxicity. Given the early discontinuation 
of the first three patients, the protocol was amended to 
shorten the first cycle to a 14-day cycle to obtain a phar-
macokinetic profile after 14 days of multiple dosing of 
LY2457546. Two more patients (D, E) were treated after 
this amendment and were discontinued on days 7 and 
17. The reason for discontinuation in these two patients 
was disease progression based on clinical symptoms. 
Three patients died a few days after discontinuation of 
LY2457546, primarily due to sepsis and progressive leuke-
mia which was no longer controlled by post-study admin-
istration of hydroxyurea. In one of the five patients (B) we 
Table 2 Baseline patient and disease characteristics (n = 5)
gender Male 3
Female 2
Age group (years) #60 1
60 4
eCOg performance 
status
0 2
1 3
Pathological diagnosis Primary AML 4
secondary AML 
(myelodysplastic syndrome)
1
Time since initial 
diagnosis (years)
#1.5 4
1.5 1
Prior antileukemia 
therapy
induction only 1
induction/consolidation 4
number of regimen
#1 1
1 4
historical illness Prostate cancer 3
Cholelithiasis 1
Venous thrombosis 2
Diverticulosis 1
Duodenal ulcer 1
Facial paresis 1
goiter 1
invertebral disc protrusion 1
Myelodysplastic syndrome 1
Osteoarthritis 1
Pneunomia 1
Polymyalgia rheumatica 1
Karyotype 46,XX,t(9;11) Patient A
46,XY,t(X;2)/47,XY,t(2;X) + 9/46,XY Patient B
47,XY,+8/46,XY Patient C
46,XY,del(11) Patient D
46,XX,del,(12),del(20)/46,XX Patient e
Abbreviations:  AML,  acute  myeloid  leukemia;  eCOg,  eastern  Cooperative 
Oncology group.Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Figure 2 Daily leukocyte and blast cell count leukocyte (upper panel) and blast cell count (lower panel) for patients A–e are displayed in relationship to the single dose and 
multiple doses of LY2457546. solid lines indicate dosing period with LY2457546, while dotted lines indicate time periods without LY2457546 treatment.
observed a significant but transient decrease in leukocyte 
and blast cell counts through day 10 (Figures 2A and 2B).
The most frequently observed adverse events in this 
study were headache, epistaxis, petechiae, and hypokalemia 
(n = 3 each, see Table 3). All these adverse events were 
graded as CTCAE 1 or 2, and were considered to be related 
to the disease rather than the study drug. Grade 3 adverse 
events included two cases of febrile neutropenia, hypoten-
sion, and infection-related adverse events, including anal 
abscess, pneumonia, catheter-related infection, fungal 
sepsis, neutropenic sepsis, and breast cellulitis (Table 3). 
As expected for this patient population, bone marrow was 
already depressed at study entry. A transient Grade 4 hypo-
phosphatemia was observed and corrected with calcium 
phosphate infusions. A Grade 4 hemorrhage was considered 
to be related to disease progression. All recorded Grade 3 
and 4 adverse events were not considered to be related to 
the study drug, with the   exception of a Grade 3 generalized 
muscle weakness in patient C, who developed this adverse 
event 14 days after starting LY2457546 administration, 
and the adverse event resolved within seven days of stop-
ping LY2457546. Because of its likely association with Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Table 3 Overview of all adverse events* regardless of causality 
(n = 5 patients)
Maximum CTC grade
system organ class
  Preferred term 1 2 3 4
Blood and lymphatic system disorders
  Febrile neutropenia 2
  splenomegaly 1
ear and labyrinthine disorders
  Vertigo 1
eye disorders
  Keratoconjunctivitis sicca 1
gastrointestinal disorders
  Chapped lips 1
  Ulcerative colitis 1
  Constipation 1 1
  Diarrhea 2
  gingival hyperplasia 1
  hemorrhoids 1 1
  inguinal hernia 1
  nausea 1
  stomatitis 1
general disorders and administration site conditions
  Asthenia (muscle weakness) 1
  Fatigue 1
  Peripheral edema 1
hepatobiliary disorders
  hepatomegaly 1
infections
  Anal abscess 1
  Breast cellulitis 1
  Catheter-related infection 1
  Fungal sepsis 1
  neutropenic sepsis 1
  Pneumonia
Metabolism and nutrition disorders
  hypokalemia 3
  hypophosphatemia 1
Musculoskeletal and connective tissue disorders
  Back pain 1
  Musculoskeletal pain 1
  Osteoporosis 1
Neoplasms (benign, malignant, and unspecified)
  hemangioma of liver 1
nervous system disorders
  headache 3
Psychiatric disorders
  Anxiety 2
  insomnia 1
Renal and urinary disorders
  Bladder spasm 1
  hematuria 1
  nephrolithiasis 1
Respiratory, thoracic and mediastinal disorders
  Asthma 1
  Cough 1
  epistaxis 1 2
  Oropharyngeal pain 1
(Continued)
Table 3 (Continued)
Maximum CTC grade
skin and subcutaneous tissue disorders
  hyperhidrosis 1
  Petechiae 3
  Facial swelling 1
  Urticaria 1
Vascular disorders
  hematoma 1
  hemorrhage 1
  hypertension 2
  hypotension 1
Note:  *Adverse  events  are  included  in  this  table  starting  from  first  dose  of 
LY2457546.
Abbreviation: CTC, Common Toxicity Criteria.
LY2457546, and after excluding other potential medical 
or drug-related causes, this toxicity was deemed to be a 
dose-limiting toxicity for this cohort.
Because other multikinase inhibitors have dose-dependent 
adverse effects on cardiac conductivity,47 cardiac monitor-
ing with a detailed QTc risk assessment was implemented 
in this study.48 In three patients abnormal electrocardio-
grams were present at study entry, which were not deemed 
medically significant. QTc prolongation after Bazet and 
Fridericia corrections were not present after the single-dose 
administration (Figure 3). Compared with baseline, the QTc 
prolongation remained unchanged over the 48-hour follow-up 
period following single-dose administration. For the multiple-
dose treatment, increased QTc prolongation was observed 
only for patient D after eight days of treatment. A relationship 
with the study drug appears unlikely, because the exposure 
of patient D to LY2457546 was lower than in other patients 
during the multiple-dose study period (Figure 3). In   addition, 
patient D also suffered from goiter and showed a steep 
decline in T3, T4, and TSH in parallel with QTc prolongation, 
strongly suggesting that thyroid function influenced the QTc 
interval (data not shown).
An unexpected pharmacokinetic profile was observed 
in all five patients, which was substantially different from 
the animal pharmacokinetic studies (data on file, Eli Lilly 
and Company, Figures 3 and 4). Extensive accumulation 
of plasma LY2457546 was observed, and the compound 
did not appear to enter an elimination phase, as assessed by 
pharmacokinetic day profiles following single (visit 0) and 
multiple oral doses (visits 1 and 2, Figures 4A, 4B, and 4C). 
As a result of this observation and the intraindividual vari-
ability of LY2457546, no terminal elimination half-life could 
be defined for any of the patients. Hence, the only reported 
parameters are Cmax, Tmax, Clast, and tlast, and the only calcu-Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
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Assessment
  Single dose 
Predosea
Postdoseb
Median (Range) 
Total number of patients 
Number of observations 
Median (Range) 
Total number of patients 
Number of observations 
458 (434 – 502) 
5
8
439 (422 – 502) 
5
5
435.6 (406.7 – 482.9)
5
24
434.3 (394.0 – 477.8)
5
20
Multiple dose 
Predosec
Postdosed
Median (Range) 
Total number of patients 
Number of observations 
Median (Range) 
Total number of patients 
Number of observations 
438 (400 – 503) 
5
5
451 (405 – 534) 
5
15 
431.5 (385.3 – 481.1)
5
15
439.25 (388.6 – 513.1)
5
44
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Figure 3 QTc assessment in relationship to plasma concentration of LY2457546. Time course of LY2457546 plasma concentrations for patients A–e (panel A). QTcB 
(panel B) and QTcF (panel C) are displayed in relationship to the single dose and multiple doses of LY2457546. A summary table of changes in QTcF and QTcB shows no 
changes in QTc compared with plasma LY2457546 concentration.
Abbreviations: QTcF, Fridericia’s corrected QTc; QTcB, Bazet’s corrected QTc.
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Figure  4  Pharmacokinetic  profile  of  LY2457546  and  the  drug–drug  interaction  cocktail  compounds  (midazolam/tolbutamide/dextromethorphan)  with  and  without 
LY2457546. Individual LY2457546 plasma concentration versus time profiles following a single dose (visit 0, panel A) and multiple oral doses of 50 mg (visit 1, panel B; visit 2, 
panel C). Midazolam (panel D), tolbutamide (panel E), and dextromethorphan (panel F) plasma concentration to time profiles following cocktail of 0.2 mg midazolam, 500 mg 
tolbutamide, and 30 mg dextromethorphan, respectively, before and after treatment with LY2457546.
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Table 4 Pharmacokinetic parameters following single and multiple oral doses of LY2457546 50 mg
Subject Tmax (h) Cmax (ng/mL) Tlast (h) Clast (ng/mL) AUClast (h*ng/mL) AUC0_24 (h*ng/mL)
Visit 0
A 48 154.876 48 154.876 6030 2520
B 2 604.581 48 302.003 16100 8930
C 4 2406.55 48 1354.06 79200 41500
D 24 105.113 24 105.113 1850 1850
e 2 394.238 24 78.459 3420 3420
n 5 5 5 5 5 5
Min 2 105.113 24 78.459 1850 1850
Max 48 2406.55 48 1354.06 79200 41500
Visit 1
A 0 619.909 24 607.429 12800 12800
B 8 591.772 24 513.075 12700 12700
C 2 3812.913 24 2830.537 69200 69100
D 2 1792.419 8 1373.021 11300 nc
e 4 123.44 48 28.097 3610 2320
n 5 5 5 5 5 3
Min 0 123.44 8 28.097 3610 2320
Max 8 3812.913 48 2830.537 69200 69100
Visit 2
A 0 1087.972 48 708.777 38400 18500
D 48 2190.006 48 2190.006 93400 41500
n 2 2 2 2 2 2
Min 0 1087.972 48 708.777 38400 18500
Max 48 2190.006 48 2190.006 93400 41500
Abbreviations: Tmax, time to maximum concentration; Cmax, maximum plasma concentration; Tlast, last time to maximum concentration; Clast, last plasma concentration; 
AUClast, last area under the plasma concentration versus time curve; min, minimum; max, maximum.
lated parameter was AUC0–24 (Table 4). Furthermore, plasma 
LY2457546 exposures were much higher than expected.
No consistent drug–drug interactions with midazo-
lam, tolbutamide, and dextromethorphan were observed 
 ( Figures 4D, 4E and 4F), suggesting that any interference 
with CYP3A4, CYPP2D6, or CYP2C9 was minimal or 
not present. This was consistent with the previous in vitro 
drug–drug interaction studies (data on file, Eli Lilly and 
Company).
In previous studies of multikinase inhibitors in AML, 
Western blotting was used to determine the pharmaco-
dynamic effects of sunitinib.32 Here, we used a novel and 
validated quantitative flow cytometry-based assay to evalu-
ate changes in phosphoprotein expression in AML blasts. 
Although we observed some variability in the makeup of 
the leukemia cell population, all five patients had CD34+ 
blasts, and three of the five patients had the CD34+CD11b- 
expression phenotype (Figure 5). Based on this expression 
of CD34 and CD11b, we defined four subgroups, which were 
evaluated for phosphoprotein expression. In all five patients, 
baseline expression of pFLT3, pcKIT, pS6, and pY100 was 
observed, especially in the CD34+CD11b- cells. However, 
pAKT, pERK, and pSTAT were not expressed (Supplemental 
Figure S1). Clear separation from the isotype controls was 
found for pFLT3, pcKIT, pS6, and pY100. As exemplified 
by the pFLT3 expression, all patients (except patient E) 
had a similar range of pFLT3 expression (Supplemental 
Figure S2). Compared with pretreatment phosphoprotein 
expression, we detected a downregulation of median phos-
phoprotein expression for pFLT3, pcKIT, and pS6 in most 
of the patients (Figure 6 and Supplemental Figure S3). 
Following single-dose administration, pFLT3, pcKIT, and 
pS6 expression was reduced at four hours after administra-
tion of LY2457546 in three of the five patients (patients A, 
C, and E, Supplemental Figure S3). After multiple dosing 
of LY2457546, we observed reduced expression of pFLT3 
and pcKIT in at least three patients (B, C, and E), and a 
similar trend was observed for pS6 in another three patients 
(patients A, B, and E, Figure 6 and Supplemental Figure S4). 
Interestingly, phosphoprotein expression increased in all 
patients at the time of progression or after treatment with 
LY2457546 had ended, and responded briefly to retreatment 
with hydroxyurea (patients B, C, and E, Figure 6, Supple-
mental Figure S4).Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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Figure 5 Flow cytometric assessment of blast cells. All blast cells were gated based on forward versus side scatter (left upper panel), and assessed for CD34 and CD11b 
expression. individual patients (A–E) are shown after adjusting for appropriate gating for CD34 and CD11b expression, establishing four different expression patterns,   
ie, CD34+CD11b-, CD34+CD11b+, CD34-CD11b-, and CD34-CD11b+.
Discussion
In the present study, we evaluated the safety and biological 
activity of LY2457546 in patients with relapsed AML. Due 
to an unfavorable pharmacokinetic profile for LY2457546, 
the study was terminated early without establishing a biologi-
cally effective dose range. When considering the conduct of 
a first-in-human dose study in patients with relapsed AML, 
it is necessary to balance the need to evaluate safety with the 
need to treat a rapidly progressing malignancy. Therefore, 
new molecular entities with an acceptable preclinical safety 
profile and antileukemic activity in animal models are con-
sidered acceptable candidates for first-in-human dose trials 
in relapsed AML patients.
In preclinical toxicology studies, LY2457546 had 
toxicities similar to those reported in nonclinical studies 
of other multikinase inhibitors, including reversible bone 
marrow toxicity, minimal liver inflammation, reversible 
physeal dysplasia (a common finding for antiangiogenic 
agents in rats and dogs),49 reversible lymphoid necrosis 
of Peyer’s patches, and skin depigmentation or whitening 
of the hair consistent with the previously described 
effects of c-KIT inhibitors.50 Overall, the preclinical 
safety profile indicated that LY2457546 had a favor-
able toxicity profile compared with other multikinase   
inhibitors.51
In addition to this favorable preclinical toxicity profile, 
the preclinical efficacy models with MV4-11 cells contain-
ing the FLT3-ITD mutation suggested that LY2457546 was 
10-fold more potent than sunitinib in controlling leukemia 
growth in animals.52 Based on these combined preclinical 
safety, efficacy, and other published inhibition profiles of 
similar multikinase inhibitors, a predictive pharmacokinetic/
pharmacodynamic model defined 50 mg per day as a starting 
dose which had the potential to provide an antileukemia effect 
in patients.38,53,54
Unfortunately, the pharmacokinetic profile of LY2457546 
in AML patients showed unexpected variability, and dif-
fered substantially from the preclinical pharmacokinetic 
data. Hence, the pharmacokinetic/pharmacodynamic model 
could not be leveraged for the first-in-human dose study. Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
168
Wacheck et al
0
0.5
1
1.5
2
2.5
3
3.5
0
0 −10 10
Treatment day (relative to visit 1 day 1)
L
e
u
k
o
c
y
t
e
s
 
[
G
/
I
]
M
E
F
L
30 50 40 20 −20
1000
2000
3000
4000
5000
6000
Leuko
pFLT3
pcKIT
pS6
Patient A
0
5
10
15
20
25
30
35
40
0
0 −101 0
Treatment day (relative to visit 1 day 1)
Patient D
L
e
u
k
o
c
y
t
e
s
 
[
G
/
I
]
M
E
F
L
30 50 40 20 −20
500
1000
1500
2000
2500
3000
Leuko
pFLT3
pcKIT
pS6
0
10
20
30
40
50
60
70
80
90
0
0 −10 10
Treatment day (relative to visit 1 day 1)
Patient E
L
e
u
k
o
c
y
t
e
s
 
[
G
/
I
]
M
E
F
L
30 50 40 20 −20
500
1000
1500
2000
2500
Leuko
pFLT3
pcKIT
pS6
0
10
20
30
40
50
60
70
80
0
0 −101 0
Treatment day (relative to visit 1 day 1)
L
e
u
k
o
c
y
t
e
s
 
[
G
/
I
]
M
E
F
L
30 50 40 20 −20
200
400
600
800
1000
1200
Patient B
Leuko
pFLT3
pcKIT
pS6
0
2
4
6
8
10
12
14
16
18
20
0
0 −10 10
Treatment day (relative to visit 1 day 1)
L
e
u
k
o
c
y
t
e
s
 
[
G
/
I
]
M
E
F
L
30 50 40 20 −20
500
1000
1500
2000
2500
3000
3500
Patient C Leuko
pFLT3
pcKIT
pS6
Figure 6 Flow cytometric assessment of pFLT3, pcKiT, and ps6 in peripheral CD34+CD11- blood cells for patients (A–E) before and after LY2457546 administration. 
expression of pFLT3, pcKiT, and ps6 at predose, day 1, day 8, day 15, and at the end of the study was measured in peripheral CD34+CD11- blood cells by fluorescence 
activated cell sorting. expression of phosphoproteins as detected by MeFL for individual patients (A–E) is shown in relationship to leukocyte counts. solid lines of leukocyte 
counts indicate dosing period with LY2457546, and dotted lines of leukocyte counts indicate time periods without LY2457546 treatment. 
Abbreviation: MEFL, molecules of equivalent fluorescence.
Variable pharmacokinetic profiles have also been reported 
for other multikinase inhibitors, such as sorafenib and 
sunitinib.55,56 In the case of LY2457546, the plasma phar-
macokinetics suggest an accumulation likely due to a lack 
of elimination or to absorption issues. Such a pharmacoki-
netic profile is not observed for sorafenib and sunitinib. 
The cause for the unexpected pharmacokinetic profile of 
LY2457546 was not identified in this study. Protein bind-
ing may have influenced the pharmacokinetic profile of 
LY2457546. All AML patients in this study had a low total 
albumin, which raises the possibility that the unbound frac-
tion of LY2457546 was larger than expected. However, no 
formal protein-binding study was conducted, and thus it was 
not possible to determine the influence of protein-binding 
on the pharmacokinetic profile of LY2457546. Like other 
multikinase inhibitors, such as imatinib and sunitinib, drugs 
altering the P450 pathway could have affected the pharma-
cokinetic profile of LY2457546.57,58 While in vitro or in vivo 
experiments with LY2457546 suggested the lack of such an 
interference (data on file, Eli Lilly and Company), animal 
models cannot definitively exclude such a risk in patients.59–63 
Hence, a drug–drug interaction assessment was conducted 
starting with the first cohort. A drug–drug interaction risk 
was not observed, as demonstrated by the unchanged plasma 
pharmacokinetics of P450 pathway enzyme substrates, ie, 
midazolam, tolbutamide, and dextromethorphan (Figure 4). 
In the future, five-drug cocktail studies may provide a more 
comprehensive assessment of how hepatic metabolism may Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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affect the pharmacokinetics of multikinase inhibitors.43 
Also, tolbutamide and midazolam are increasingly dif-
ficult to obtain for drug–drug interaction studies, because 
their pharmaceutical use is in decline or restricted in most 
European Union countries. Another factor influencing the 
pharmacokinetic profile of LY2457546 is stomach acidity, 
which may have affected the absorption of LY2457546.64 
For instance, four of our five patients were taking a proton 
pump inhibitor (pantoprazole), which may have altered the 
pharmacokinetics of LY2457546. Further, enterohepatic 
recycling of LY2457546 may also explain the unexpected 
pharmacokinetic profile. In both instances, a change in for-
mulation of LY2457546 may help to address the observed 
unfavorable pharmacokinetic profile.
Despite this pharmacokinetic profile, there was little or 
no drug-associated QTc prolongation. Some central health 
authorities have expressed the concern that QTc studies are not 
adequately conducted in oncology trials.65 However, evaluating 
the risk of QTc prolongation in cancer patients is not straight-
forward. When the pharmacokinetic profile is not known in a 
first-in-human dose trial, the assessment of QTc risk is further 
complicated by the overall condition of the study population, 
consisting of terminally ill patients with heavily pretreated 
conditions receiving several comedications and suffering 
from coexisting disease. Most patients in our study had pre-
viously received multiple cycles of anthracycline-based che-
motherapy as part of their induction/consolidation treatment. 
Other potentially cardiotoxic comedications having a definite 
association with QTc prolongation,66 such as amitriptyline, 
diphenhydramine, pantoprazole, fluconazole, ketoconazole, 
azithromycin, and ciprofloxacin, were identified in this study, 
but were not associated with QTc prolongation. Pre-existing 
medical conditions of patients in this study were more likely 
to interfere with electrocardiographic interpretation, ie, arte-
rial hypertension Grade 2 (patient C), goiter (patient D), and 
asthma (patient E). QTc studies are generally conducted in 
healthy volunteers after the pharmacokinetic profile of an agent 
is well established.47 However, recent requests from competent 
health authorities to investigate QTc as part of oncology first-
in-human dose studies may be more motivated by concerns 
about the conductivity risk for specific drug classes (as in 
this case, where LY2457546 was classified as belonging to 
the multikinase inhibitor class, which also includes sunitinib 
and sorafenib). In contrast with other approved multikinase 
inhibitors, LY2457546 did not show significant electrophysi-
ological toxicity in animals. While the potential risk of QTc 
prolongation was raised when LY2457546 was found to 
inhibit the human ether-à-go-go-related gene (hERG) at an 
IC50 of 0.2 μM, no QTc interval prolongation was observed 
in electrocardiograms after single or repeat doses in dogs at 
maximal plasma concentrations of up to 7 μg/mL (data on 
file, Eli Lilly and Company). Hence, it was reassuring that 
we only observed QTc prolongation in a patient with goiter 
(patient D) which was not associated with high LY2457546 
concentration (Figure 3).
The Grade 3 muscle weakness in one patient was remi-
niscent of a similar toxicity in AML patients observed with 
MS-275, a histone deacetylase inhibitor.67 MS-275 was asso-
ciated with Grade 4 neurologic toxicity, consisting of som-
nolence, weakness, and unsteady gait, and associated with 
Grade 3 laboratory abnormalities, including elevated lactate 
dehydrogenase, hypertriglyceridemia, and hyperglycemia.67 
Also, in AML studies with MLN518/tandutinib, three cases 
of tandutinib-related muscular weakness were reported as 
dose-limiting toxicities.27 Based on a recent review of several 
FLT3 inhibitors, muscle weakness toxicity is considered an 
exception among other FLT3 inhibitors. The neurotoxicities 
observed with MS-275 and MLN518 are perhaps due to the 
broad inhibition profile of such type of inhibitors, which may 
include inhibition of the muscle-type nicotinic receptor.68 For 
LY2457546, no such inhibition of a muscle-type nicotinic 
receptor has been evaluated.
Finally, we measured the pharmacodynamic effects 
of LY2457546 by assessing changes of phosphoproteins 
in blast cells using quantitative flow cytometry69 and not 
Western blotting.32 Western blotting was used in studies 
with sunitinib, where a reduction of pFLT3 was reported in 
77% patients (10/13) at 200 mg, while lower doses showed a 
pFLT3 reduction in 25% of the patients (2/8). Western blot-
ting was also used to detect a reduction in pFLT3 expression 
after 300 mg and 525 mg twice-daily dosing with MLN518/
tandutinib.27 In contrast with Western blotting, the recent 
progress in flow cytometry allows a quantitative assessment 
of basal expression of phosphoproteins70 and treatment-
associated monitoring of signaling pathways.45,71 Based on 
the predictive pharmacokinetic/pharmacodynamic model, 
we expected an inhibition of most phosphoprotein kinases 
at the 50 mg/day dose. In fact, the flow cytometry studies 
showed an inhibition for pFLT3, pcKIT, and pS6 in three of 
our five patients. Surprisingly, pAKT and pERK expression 
was absent in all patients. This failure of detecting pAKT 
and pERK might be due to either a loss of expression during 
sample shipment or the lack of expression in patients with 
advanced AML. While we achieved reductions in pFLT3 
levels after LY2457546 administration, the reduction was 
not associated with a durable reduction in blast cell counts. Cancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
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It is possible that flow cytometry is a more sensitive assay 
compared with Western blotting, and thus the 50 mg/day 
dose of LY2457546 was a threshold dose above which 
antileukemic responses may have occurred as predicted 
by the pharmacokinetic/  pharmacodynamic model. Unfor-
tunately, we were not able to evaluate the possibility of a 
dose-dependent increase in phosphoprotein inhibition and 
its associated antileukemic effect in this study. Neverthe-
less, the approach of using multiparametric flow cytometry 
is encouraging, and should be further evaluated in clinical 
trials with similar agents.
Overall, this first-in-human dose study provides a detailed 
approach on how to integrate the evaluation of safety (includ-
ing concentration-associated QTc assessments as part of 
the definition of dose-limiting toxicity), pharmacokinetics 
and pharmacodynamics of a multikinase inhibitor in AML 
patients.
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Figure S1 Flow cytometric assessment of phosphoproteins (pFLT3, pCKiT, ps6, pY100, peRK, pAkt, and psTAT5) in peripheral CD34+CD11- blood cells of five patients 
treated with a single dose and multiple doses of LY2457546. Summary representation of all five patients for pFLT3 (red), pcKIT (green), pS6 (pink), and pY100 (yellow) at 
predose, and after 8 and 15 days of treatment with LY2457546. Reduction of pFLT3, pcKiT and ps6 at day 8 was observed in most patients, which increased at day 15. peRK 
(orange), pAKT (gray), and psTAT5 (cyan) expression was not detectable. Phosphoprotein expression is plotted as MeFL.
Abbreviation: MEFL, molecules of equivalent fluorescence.
Supplementary figuresCancer Management and Research 2011:3 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
174
Wacheck et al
0
500
1000
1500
2000
2500
3000
3500
6 h 4 h 8  h
LY2457546 single dose
A
LY2457546 multiple dose
p
F
L
T
3
 
[
M
E
F
L
]
24 h Pre
dose
6 h 4 h 8  h 24 h 0 h
C
0
100
200
300
400
500
600
700
p
S
6
 
[
M
E
F
L
]
6 h 4 h 8  h
LY2457546 single dose LY2457546 multiple dose
24 h Pre
dose
6 h 4 h 8  h 24 h 0 h
B
A
C
D
E
B
A
C
D
E
B
0
1000
2000
3000
4000
5000
6000
p
c
K
I
T
 
[
M
E
F
L
]
6 h 4 h 8  h
LY2457546 single dose LY2457546 multiple dose
24 h Pre
dose
6 h 4 h 8  h 24 h 0 h
B
A
C
D
E
Figure S3 Flow cytometric assessment of pFLT3, pcKiT, and ps6 in patients treated with a single dose followed by multiple doses of LY2457546 in peripheral CD34+CD11- 
blood cells. Individual pharmacodynamic profiles of pFLT3 (A), pcKiT (B), and ps6 (C) expression following single-dose and multiple-dose LY2457546. Phosphoprotein 
expression is presented as MeFL. Reduction of phosphoprotein expression begins four hours after administration of LY2457546.
Abbreviation: MEFL, molecules of equivalent fluorescence.
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Figure S2 Differentiation of isotype control and pFLT3 detection in five AML patients by flow cytometry. Each patient (A–E) is shown for their pFLT3 expression in 
peripheral blood cells after gating on CD34+CD11- blood cells (see Figure 4). Changes are shown after single dosing followed by multidosing with LY2457546. The black lines 
represent pFLT3 expression as detected by MeFL, while the gray lines represent the respective isotype control.
Abbreviations: AML, acute myeloid leukemia; MEFL, molecules of equivalent fluorescence.Cancer Management and Research
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Figure S4 Flow cytometric assessment of pFLT3, pcKiT, and ps6 in peripheral CD34+CD11- blood cells relative to blast cell counts for patients (A–E) following administration 
of LY2457546. expression of pFLT3, pcKiT, and ps6 at predose, day 1, day 8, day 15, and at the end of the study was measured in peripheral CD34+CD11- blood cells by 
fluorescence activated cell sorting. Expression of phosphoproteins as detected by MEFL for individual patients. Patients (A–E) are shown in relationship to blast counts. solid 
lines of blast counts indicate dosing period with LY2457546 while dotted lines of blast counts indicate time periods without LY2457546.
Abbreviation: MEFL, molecules of equivalent fluorescence.